HS delay in Dx a worldwide problem leading to complications

Based on the comparatively unique presentation of hidradenitis suppurativa (HS) and its known psychological impacts, an international team has developed a HS-specific quality of life (QoL) measure. Part of the rationale for developing this measure is that research into development of new treatments of HS will require measures of improvement that address patient-reported outcomes, rather than just clinical outcomes, senior author Dr. Jerry Tan told DERM.city. The typical locat

Early diagnosis and aggressive treatment of hidradenitis suppurativa (HS) is important and can make a significant difference in the lives of these patients, according to Toronto-based dermatologist Dr. Afsaneh Alavi. “HS is a chronic and debilitating disease that commonly [occurs] in the young population of patients after puberty. HS is three times more common in female patients,” said Dr. Alavi, speaking at the 3rd annual Skin Spectrum Summit in Toronto on Apr. 8, 2017. Dr.

Therapies for hidradenitis suppurativa (HS)/acne inversa should be based upon evaluation of the inflammatory components, as well as the scarring, and should be directed by an evidence-based approach, according to a study published in the journal Reviews in Endocrine and Metabolic Disorder (September 2016; 17(3):343–351). “We wanted an evidence-based approach because the treatment of HS—until the publication of the European [Dermatology Forum] guidelines—had been based somewha

There appears to be a delay in the diagnosis of patients with hidradenitis suppurativa (HS), according to researchers who reported findings of a Canadian epidemiological multicenter, cross-sectional retrospective study. This study, published in the Journal of Cutaneous Medicine and Surgery (Jan. 2016; 20(1):52–57), was discussed by senior author Dr. Afsaneh Alavi during a joint presentation with Dr. Melinda Gooderham at the fall 2015 sessions of Dermatology Update in Toronto.